Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694198 | 0.80 | ALOX15 (0.40) | LMNAALOX15POLBALDH1A1HPGD | |
| SCHEMBL16648595 | 0.79 | SYK (0.50) | CDK1LMNAALDH1A1TOP2A | |
| SCHEMBL134909 | 0.78 | PDPK1 (0.49) | PDPK1GDAMGMTCDK1CDK2 | |
| SCHEMBL8581232 | 0.77 | CDK1 (0.52) | PDPK1GDAMGMTCDK1CDK2 | |
| SCHEMBL29509029 | 0.76 | GDA (0.58) | PDPK1GDAMGMTCDK2CYP1A2 | |
| SCHEMBL1684049 | 0.76 | GDA (0.58) | PDPK1GDAMGMTCDK2CYP1A2 | |
| SCHEMBL30107648 | 0.75 | GDA (0.56) | PDPK1GDAMGMTCDK2CYP1A2 | |
| SCHEMBL9393667 | 0.75 | PDPK1 (0.49) | PDPK1GDAMGMTCDK1CDK2 | |
| SCHEMBL9458749 | 0.74 | ADORA3 (0.55) | PDPK1GDAMGMTCDK1CDK2 | |
| SCHEMBL27461919 | 0.73 | GDA (0.58) | PDPK1GDAMGMTCDK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | claimed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | claimed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140038181-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES, INC. | 2014-02-06 | — | — | US | disclosed |
| WO-2012094343-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, FBP1, PNKP | PDPK1 1748/4885GDA 402/4885MGMT 1561/4885 |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | PDPK1 2015/4885GDA 488/4885MGMT 1413/4885 |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, TYMP, PAICS | PDPK1 2015/4885GDA 488/4885MGMT 1413/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | PDPK1 3656/4885GDA 716/4885MGMT 408/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | PDPK1 2015/4885GDA 488/4885MGMT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.